Help support our Research! Learn More & Donate Today

2007 ACR CME Activity - Skyscape Edition

Skyscape CME STAT provides a three-part CME/CE activity series that will share highlights of key information presented at the 71st Annual American College of Rheumatology Meeting.  CME STAT enables you to participate in this series on any platform – mobile device, PDA, Smartphone, laptop, or desktop PC. 
Each day of activity covers the following:

  • Day 1: Treatment of rheumatoid arthritis (RA); including New RA Treatments and Current RA Therapies, and osteoporosis in RA patients
    Presented on Thursday, November 8th, 2007 in Boston, MA
  • Day 2: New insights into the pathogenesis, diagnosis, and treatment of several systemic rheumatic diseases.  
    Presented on Thursday, November 8th and Friday, November 9th, 2007 in Boston, MA.
  • Day 3: Insights into the genetic risk factors for rheumatic diseases, new biomarkers for disease activity, the impact of new treatment options for rheumatoid arthritis (RA), how to handle special situations in patients on biologic therapy, and outcomes in patients with systemic lupus erythematosus (SLE)
    Presented on Saturday, November 10th, in Boston, MA.
  • Sign up for Skyscape CME STAT and to participate in this activity.

AddThis Social Bookmark Button

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

ACR Podcasts

  • ACR Day One Podcast:Treatment of rheumatoid arthritis (RA); including New RA Treatments and Current RA Therapies, and osteoporosis in RA patients.
  • ACR Day 2 Podcast:New insights into the pathogenesis, diagnosis, and treatment of several systemic rheumatic diseases.
  • ACR Day 3 Podcast:Insights into the genetic risk factors for rheumatic diseases, new biomarkers for disease activity, the impact of new treatment options for rheumatoid arthritis (RA), how to handle special situations in patients on biologic therapy, and outcomes in patients with systemic lupus erythematosus (SLE).

Signup For Our Email Newsletter